Recently added articles from Biotech Business:
RXI ACQUIRES OWNERSHIP OF PREVIOUSLY LICENSED RNAI DELIVERY.
Nov 01, 2009; ... RXi Pharmaceuticals Corporation (Nasdaq: RXII), Worcester, Mass., a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), has recently acquired direct ownership of technology for which it had previously ...
ICAGEN INITIATES PROOF-OF-CONCEPT OF ICA-105665 IN EPILEPSY.
Nov 01, 2009; ... Icagen, Inc. (Nasdaq:ICGN), Research Triangle Park, N.C., has announced the initiation of a proof-of-concept study of ICA-105665 in patients with photosensitive epilepsy. ICA- 105665 is a novel, orally available opener of subtypes of KCNQ channels, which have been validated by both genetic ...
VICAL PRESENTS POSITIVE PRECLINCAL RESULTS WITH VAXFECTIN.
Nov 01, 2009; ... Vical Incorporated (Nasdaq:VICL), has announced encouraging results from animal studies of a peptide-based cancer vaccine formulated with the company's Vaxfectin(R) adjuvant. Sean M. Sullivan, Ph.D., Vical's Executive Director of Pharmaceutical Sciences, has presented data at the IIRUSA ...
CHELSEA REPORTS PRELIMINARY PHASE III DROXIDOPA DATA.(Clinical report)
Nov 01, 2009; ... Chelsea Therapeutics International, Ltd.(Nasdaq:CHTP), Charlotte, N.C., has announced top-line results from Study 302, the first of two Phase III trials of Droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). While Study 302 demonstrated that Droxidopa ...
